Psychedelics Company MindMed Prices Public Offering Aiming To Raise $75M
Psychedelics Company MindMed Prices Public Offering Aiming To Raise $75M
Leerink Partners and Evercore ISI are acting as the joint bookrunning managers for the offering. RBC Capital Markets and Oppenheimer & Co. are acting as lead managers.A psychedelics-focused biopharmaceutical company Mind Medicine (MindMed) (NASDAQ:MNMD) announced Friday the pricing of an underwritten public offering of 9.29 million shares without par value, at a price of $7.00 per share. Through this round, the New York-headquartered company aims to raise $75 million.
心灵医药（MindMed）是一家以致幻剂为重点的生物制药公司（纳斯达克：MNMD），于周五宣布了一项929万股无面值的被承销公开发行价格为每股7.00美元的发行计划。通过这轮融资，总部位于纽约的公司旨在筹集7500万美元。
MindMed also announced offering pre-funded warrants to certain investors, allowing them to buy 1.43 million shares at a price of $6.999 per pre-funded warrant.
MindMed还宣布向某些投资者提供预先拟定的认股权证，允许他们以6.999美元每股的价格购买143万股认股证权。
The company intends to use the proceeds from the offering to support the research and development of its product candidates, working capital and general corporate purposes.
该公司打算利用此次发行所得收益支持其产品候选品的研发、工作资本以及一般企业用途。
Leerink Partners and Evercore ISI are acting as the joint bookrunning managers for the offering. RBC Capital Markets and Oppenheimer & Co. are acting as lead managers.
Leerink Partners和Evercore ISI担任本次发行的联席承销商，RBC资本市场和Oppenheimer＆Co.担任主要经纪人。
The offering is expected to close on or about August 12, 2024, subject to the satisfaction of customary closing conditions. No distribution under the offering shall occur in Canada or to a person resident in Canada.
本次发行预计将于2024年8月12日左右结束，视乎符合惯例的交割条件。在加拿大境内或任何加拿大常住居民处不得进行本次发行。
Read Also: EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
阅读更多：独家报道：法律认可的魔菇产品将在牙买加出售，随着psilocybin产品进入药房货架
The offering comes about a month after the company announced the issuance of a new patent by the U.S. Patent and Trademark Office (USPTO) covering MM120 (lysergide). MM120 is currently in clinical development for adults with generalized anxiety disorder (GAD) and presents opportunities for treating a range of additional brain health disorders.
本次发行约一个月前，该公司宣布美国专利局（USPTO）颁发了一项新专利，涵盖了MM120（麦角酸二乙酰胺）。MM120目前正在针对广泛性焦虑症（GAD）的成年人进行临床开发，并为治疗一系列其他大脑健康疾病提供了机会。
The newly issued patent (USPN 12,036,220) includes claims covering the pharmaceutical formulation, methods of manufacturing and method of treatment for MM120 ODT, MindMed's proprietary and pharmaceutically optimized form of lysergide (LSD). The pharmaceutical formulation patent is the first US patent issued on the MM120 ODT formulation and extends the company's intellectual property protection for MM120 through 2041.
新颁发的专利（USPN 12,036,220）包括涵盖药物配方、制造方法和MM120 ODt治疗方法的声明，MindMed的专有和药学优化的麦角酸二乙酰胺（LSD）形式。药物配方专利是首个针对MM120 ODt配方的美国专利，并将MindMed的知识产权保护延伸到2041年。
Price Action
股价变动
MindMed shares traded 2.32% lower at $6.75 per share during Monday's pre-market session.
MindMed股票在周一盘前交易中下跌2.32％，每股6.75美元。
- FDA Rejects MDMA For PTSD Treatment, Calls For More Research On Psychedelic Therapy
- FDA拒绝将MDMA用于创伤后应激障碍的治疗并呼吁进行更多有关精神疗法的研究。
Photo: Generated with AI
图片：通过人工智能生成
